The Bull Case For Alkermes (ALKS) Could Change Following Vibrance-12 Data And Russell 2000 Inclusion

Simply Wall St.

07/04

In late June 2026, Alkermes plc reported positive Phase 2 Vibrance-12 results for its oral orexin 2 receptor agonist alixorexton in narcolepsy type 2, while also being added to the Russell 2000 ...

网页链接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2648969621"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2648969621\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2648969621?lang=zh_TW&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-07-04 15:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2648969621","market":"hk","top_or_hot":-1,"title":"The Bull Case For Alkermes (ALKS) Could Change Following Vibrance-12 Data And Russell 2000 Inclusion","media":"Simply Wall St.","content":"<div>\n<p>In late June 2026, Alkermes plc reported positive Phase 2 Vibrance-12 results for its oral orexin 2 receptor agonist alixorexton in narcolepsy type 2, while also being added to the Russell 2000 ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alks/alkermes/news/the-bull-case-for-alkermes-alks-could-change-following-vibra\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bull Case For Alkermes (ALKS) Could Change Following Vibrance-12 Data And Russell 2000 Inclusion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bull Case For Alkermes (ALKS) Could Change Following Vibrance-12 Data And Russell 2000 Inclusion\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Simply Wall St.</strong><span class=\"h-time small\">2026-07-04 15:22</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>In late June 2026, Alkermes plc reported positive Phase 2 Vibrance-12 results for its oral orexin 2 receptor agonist alixorexton in narcolepsy type 2, while also being added to the Russell 2000 ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alks/alkermes/news/the-bull-case-for-alkermes-alks-could-change-following-vibra\">网页链接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alks/alkermes/news/the-bull-case-for-alkermes-alks-could-change-following-vibra\">Simply Wall St.</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KAUG","symbol_name":"Innovator U.S. Small Cap Power Buffer ETF - August","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alks/alkermes/news/the-bull-case-for-alkermes-alks-could-change-following-vibra","article_id":"2648969621","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alks/alkermes/news/the-bull-case-for-alkermes-alks-could-change-following-vibra","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2648969621","pubTimestamp":1783149726,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In late June 2026, Alkermes plc reported positive Phase 2 Vibrance-12 results for its oral orexin 2 receptor agonist alixorexton in narcolepsy type 2, while also being added to the Russell 2000 Dynamic Index.\nThe combination of clinically meaningful wakefulness and safety data with inclusion in a major benchmark index strengthens Alkermes’ profile in sleep medicine and broadens its visibility with institutional investors.\nNext, we’ll examine how the Vibrance-12 alixorexton data could reshape...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"KAUG":"Innovator U.S. Small Cap Power Buffer ETF - August","VTWO":"Vanguard Russell 2000 ETF","GSSC":"Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF","SVAL":"iShares US Small Cap Value Factor ETF","SAWS":"AAM SAWGRASS US SMALL CAP QUALITY GROWTH ETF","FSMD":"Fidelity Small-Mid Multifactor ETF","RFLR":"Innovator U.S. Small Cap Managed Floor ETF","IWMI":"NEOS Russell 2000 High Income ETF","TNA":"罗素2000指数三倍做多ETF-Direxion","IJR":"标普小型股600指数ETF-iShares","SCAP":"INFRACAP SMALL CAP INCOME ETF","ISMD":"Inspire Small/Mid Cap ETF","JPSE":"JPMorgan Diversified Return U.S. Small Cap Equity ETF","WCEO":"HYPATIA WOMEN CEO ETF","KJAN":"Innovator U.S. Small Cap Power Buffer ETF - January","OMFS":"Invesco Russell 2000 Dynamic Multifactor ETF","FDM":"First Trust/First Trust Dow Jone","IWMY":"Defiance R2000 Enhanced Options & 0DTE Income ETF","OVS":"Overlay Shares Small Cap Equity ETF","FSCS":"First Trust SMID Capital Strength ETF","UWM":"罗素2000指数ETF两倍做多","SAUG":"FT Vest U.S. Small Cap Moderate Buffer ETF - August","OASC":"OneAscent Small Cap Core ETF","KOCT":"Innovator U.S. Small Cap Power Buffer ETF - October","URTY":"ProShares UltraPro罗素2000","GSC":"GOLDMAN SACHS SMALL CAP CORE EQUITY ETF","KJUL":"Innovator U.S. Small Cap Power Buffer ETF - July","RSSL":"Global X Russell 2000 ETF","ESIX":"SPDR S&P SMALLCAP 600 ESG ETF","KSEP":"Innovator U.S. Small Cap Power Buffer ETF - September","ALKS":"阿尔凯默斯","IWML":"ETRACS 2x Leveraged US Size Factor TR ETN","KAPR":"Innovator U.S. Small Cap Power Buffer ETF - April","SCDS":"JPMorgan Fundamental Data Science Small Core ETF","TWM":"罗素2000指数两倍做空ETF","SMAY":"FT Vest U.S. Small Cap Moderate Buffer ETF - May","XJR":"iShares ESG Select Screened S&P Small-Cap ETF","MYLD":"Cambria Micro and Small Cap Shareholder Yield ETF","SCDV":"BAHL & GAYNOR SMALL CAP DIVIDEND ETF","SRTY":"罗素2000指数三倍做空ETF-ProShares","RYLD":"Global X Russell 2000 Covered Call ETF","NBSM":"Neuberger Berman Small-Mid Cap ETF","AVSC":"AVANTIS U.S. SMALL CAP EQUITY ETF","RYLG":"Global X Russell 2000 Covered Call & Growth ETF","PSC":"Principal U.S. Small-Cap Multi-Factor ETF","DFAS":"Dimensional U.S. Small Cap ETF","TZA":"罗素2000指数三倍做空ETF","CPRO":"CALAMOS RUSSELL 2000 STRUCTURED ALT PROTECTION ETF - OCTOBER","HAPS":"Harbor Human Capital Factor US Small Cap ETF","RWM":"罗素2000指数反向ETF"},"translate_title":"Vibrance-12数据和Russell 2000纳入后，Alkermes(ALKS)的牛市可能会发生变化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WCEO":1.5,"RYLG":1.5,"DFAS":1.5,"GSC":1.5,"JPSE":1.5,"KAUG":1.5,"KJAN":1.5,"TNA":1.5,"VTWO":1.5,"RWM":1.5,"KAPR":1.5,"HAPS":1.5,"XJR":1.5,"IWMI":1.5,"MYLD":1.5,"ISMD":1.5,"KOCT":1.5,"RFLR":1.5,"SCDS":1.5,"FSCS":1.5,"IWMY":1.5,"SCDV":1.5,"FSMD":1.5,"UWM":1.5,"GSSC":1.5,"IJR":1.5,"OMFS":1.5,"SAUG":1.5,"TWM":1.5,"TZA":1.5,"SRTY":1.5,"PSC":1.5,"ESIX":1.5,"KJUL":1.5,"SVAL":1.5,"SMAY":1.5,"SCAP":1.5,"NBSM":1.5,"AVSC":1.5,"RYLD":1.5,"RSSL":1.5,"OASC":1.5,"ALKS":1.5,"IWML":1.5,"CPRO":1.5,"URTY":1.5,"SAWS":1.5,"OVS":1.5,"FDM":1.5,"KSEP":1.5},"content_text":"In late June 2026, Alkermes plc reported positive Phase 2 Vibrance-12 results for its oral orexin 2 receptor agonist alixorexton in narcolepsy type 2, while also being added to the Russell 2000 Dynamic Index. The combination of clinically meaningful wakefulness and safety data with inclusion in a major benchmark index strengthens Alkermes’ profile in sleep medicine and broadens its visibility with institutional investors. Next, we’ll examine how the Vibrance-12 alixorexton data could reshape Alkermes’ orexin franchise narrative and long-term growth balance. We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.AdvertisementAlkermes Investment Narrative RecapTo own Alkermes today, you need to believe that its orexin program, led by alixorexton, can evolve into a meaningful new sleep franchise alongside Vivitrol, Aristada and Lybalvi. The latest Vibrance-12 Phase 2 data in narcolepsy type 2 and inclusion in the Russell 2000 Dynamic Index both reinforce the importance of the Brilliance Phase 3 program as the key near term catalyst, while late stage trial and regulatory outcomes remain the biggest swing risk. Among recent announcements, the launch of the global Phase 3 Brilliance program for alixorexton ties most directly to the Vibrance-12 update. The Phase 2 results in narcolepsy type 2 strengthen the clinical rationale for this program, but they do not remove the execution and outcome risks around Phase 3 trial performance, regulatory expectations on endpoints like wakefulness and potential safety scrutiny across the orexin class. Yet against this clinical momentum, investors still need to watch the unresolved regulatory risk around orexin safety and label restrictions that could... Read the full narrative on Alkermes (it's free!)Alkermes' narrative projects $2.1 billion revenue and $264.8 million earnings by 2029. This requires 11.1% yearly revenue growth and about a $112 million earnings increase from $152.7 million today.Uncover how Alkermes' forecasts yield a $47.69 fair value, a 13% downside to its current price.Exploring Other PerspectivesALKS 1-Year Stock Price Chart Some of the lowest ranked analysts were expecting Alkermes revenue to fall to about US$1.3 billion and earnings to about US$183.7 million, highlighting how much more cautious they were about orexin competition and pricing pressure, even before this latest Vibrance update, and reminding you that views on the same data can differ widely.Explore 5 other fair value estimates on Alkermes - why the stock might be worth as much as 86% more than the current price!Reach Your Own ConclusionDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Alkermes research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.Our free Alkermes research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Alkermes' overall financial health at a glance.Ready To Venture Into Other Investment Styles?Our top stock finds are flying under the radar-for now. Get in early:The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.Uncover the next big thing with 20 elite penny stocks that balance risk and reward.Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}